$132.17
-0.87[-0.65%]
At close: May 17
$132.17
0[0.00%]
PreMarket: 4:19AM EDT
Novo Nordisk
(NYSE:NVO)Latest News for Novo Nordisk Stock (NYSE:NVO)
Novo Nordisk Stock (NYSE: NVO)
Categories: All
Thursday, May 16, 2024
Wednesday, May 15, 2024
- 13F Shows Soros Fund Management LLC Decreased Stake in Novo-Nordisk A S by 757.21K Shares, or -49%, to 797.62K Shares, Valued at $102.41MBenzinga Newsdesk - 1 day ago
- Should You Hold Viking Therapeutics in Your Portfolio?Zacks - 1 day ago
- No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk ConfirmsVandana Singh - 1 day ago
- Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And ZepboundVandana Singh - 1 day ago
Tuesday, May 14, 2024
- Eli Lilly Provides Update On Mounjaro And Zepbound Compounding Litigation; Enters Settlement Requiring Totality Medispa To Make Monetary Payment, Prohibiting Misleading Conduct, And Reporting Adverse Events To FDABenzinga Newsdesk - 2 days ago
- 'Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs' - WSJBenzinga Newsdesk - 2 days ago
- Spotlight on Novo Nordisk: Analyzing the Surge in Options ActivityBenzinga Insights - 2 days ago
- Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And GovernmentsBenzinga Neuro - 3 days ago
Monday, May 13, 2024
- Novo Nordisk shares are trading higher after the company announced the FRONTIER 2 trial achieved its co-primary endpoints.Benzinga Newsdesk - 3 days ago
- Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing FrequencyVandana Singh - 3 days ago
- Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia ABenzinga Newsdesk - 3 days ago
- Novo Nordisk Announces Headline Results From The FRONTIER 2 Trial; Achieved Its Co-Primary Endpoints By Demonstrating A Reduction Of Treated Bleeding Episodes With Both Once-Weekly And Once-Monthly Mim8 Versus No Prophylaxis Treatment And Prior Coagulation Factor Prophylaxis TreatmentBenzinga Newsdesk - 3 days ago
Thursday, May 09, 2024
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - May 9, 2024, 1:35PM
- Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone PaymentsBenzinga Newsdesk - May 9, 2024, 8:26AM
Tuesday, May 07, 2024
Sunday, May 05, 2024
Friday, May 03, 2024
- Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc ClaimsZacks - May 3, 2024, 4:00PM
- Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running UpThe Arora Report - May 3, 2024, 10:58AM
- Job Market Cools In April: Payrolls Miss Forecasts, Wages Rise Less Than Expected (UPDATED)Piero Cingari - May 3, 2024, 8:58AM
- Lilly and Novo Nordisk shares are trading lower following a weight loss drug update from Amgen.Benzinga Newsdesk - May 3, 2024, 8:20AM
Thursday, May 02, 2024
- Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and MounjaroVandana Singh - May 2, 2024, 4:01PM
- Novo Nordisk shares are trading lower following Q1 earnings.Benzinga Newsdesk - May 2, 2024, 9:57AM
- Alkermes Has Completed The Previously Announced Sale Of Its Development And Manufacturing Facility In Athlone, Ireland To Novo Nordisk, Alkermes Will Receive A One-time Cash Payment Of Approximately $91MBenzinga Newsdesk - May 2, 2024, 8:04AM
- Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly CompetitionBenzinga Neuro - May 2, 2024, 5:48AM
- Novo Nordisk Updates 2024 Outlook, Now Expects Sales Growth Of 19%-27% (Prior 18%-26%) And Operating Profit Growth Of 22%-30% (Prior 21%-29%)Benzinga Newsdesk - May 2, 2024, 2:09AM
- Novo Nordisk Q1 2024 GAAP EPS DKK 5.68 Beats DKK 5.15 Estimate, Sales DKK 65.349B Beat DKK 63.229B EstimateBenzinga Newsdesk - May 2, 2024, 2:02AM
Wednesday, May 01, 2024
- Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZenecaVandana Singh - May 1, 2024, 4:11PM
- Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For OzempicBenzinga Neuro - May 1, 2024, 10:44AM
Monday, April 29, 2024
- Decoding Novo Nordisk's Options Activity: What's the Big Picture?Benzinga Insights - Apr 29, 2024, 3:01PM
- FDA Says Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml (NDC 0169-4517-14) Is AvailableBenzinga Newsdesk - Apr 29, 2024, 11:34AM
- FDA Says Novo's Wegovy, Injection, .25 mg/.5 ml (NDC 0169-4525-14) Under Limited Availability With Estimated Shortage Duration TBD; Wegovy, Injection, .5 mg/.5 ml (NDC 0169-4505-14) Under Limited Availability With Estimated Shortage Duration TBD; Wegovy, Injection, 1 mg/.5 ml (NDC 0169-4501-14) Limited Availability With Estimated Shortage Duration TBDBenzinga Newsdesk - Apr 29, 2024, 11:25AM
Friday, April 26, 2024
Wednesday, April 24, 2024
- What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo NordiskVandana Singh - Apr 24, 2024, 2:14PM
- "Senate Committee Investigates Ozempic And Wegovy Costs; Senator Bernie Sanders Is Pressing The Drugmaker Novo Nordisk For Details On Its Pricing Of The Popular Diabetes And Weight Loss Medications" - NY TimesBenzinga Newsdesk - Apr 24, 2024, 12:03PM
Monday, April 22, 2024
Thursday, April 18, 2024
- German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs PipelineVandana Singh - Apr 18, 2024, 1:55PM
- Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025Vandana Singh - Apr 18, 2024, 12:50PM
- Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price TargetBenzinga Newsdesk - Apr 18, 2024, 9:59AM
Wednesday, April 17, 2024
Monday, April 15, 2024
Friday, April 12, 2024
- Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform RatingVandana Singh - Apr 12, 2024, 1:22PM
- Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding PharmacyVandana Singh - Apr 12, 2024, 11:54AM
- Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency SaysVandana Singh - Apr 12, 2024, 10:40AM
- Novo Nordisk shares are trading higher after EU regulators reportedly ruled out a link between wight loss drugs and suicidal thoughts. Additionally, BMO Capital initiated coverage on the stock with an Outperform rating.Benzinga Newsdesk - Apr 12, 2024, 9:37AM
- Pharmacovigilance Risk Assessment Committee Clears GLP-1 Diabetes Medications of Causing Suicidal or Self-Injurious BehaviorBenzinga Newsdesk - Apr 12, 2024, 8:02AM
- BMO Capital Initiates Coverage On Novo Nordisk with Outperform Rating, Announces Price Target of $163Benzinga Newsdesk - Apr 12, 2024, 5:15AM